Novartis (NVS): New Data From PARADIGM-HF Shows LCZ696 Cut Incidence of Sudden Deaths
Tweet Send to a Friend
New data on Novartis' (NYSE: NVS) investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction (HFrEF) shows ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
